www.fdanews.com/articles/132132-archemix-sells-hemophilia-drug-assets-to-baxter-for-up-to-305-million
Archemix Sells Hemophilia Drug Assets to Baxter for up to $305 Million
November 22, 2010
Cambridge-based Archemix Corp. has agreed to sell all of its hemophilia-related assets to Illinois life sciences company Baxter International Inc. for a deal that could be worth up to $305 million for Archemix.
Mass High Tech
Mass High Tech